IA Trial Radar

Découvrons ensemble les essais cliniques avec Bavarian Nordic en tant que promoteur principal ou collaborateur.

Je peux vous aider à comprendre votre état de santé, les traitements ou à trouver des essais cliniques près de chez vous.
Notre outil de recherche ne prend en charge que l'anglais. Pour la recherche et la discussion dans d'autres langues, utilisez l'IA Trial Radar ci-dessus ou sélectionnez les filtres de condition médicale et de lieu ci-dessous.
40 essais cliniques
 
Sexe
Tous
×
 
Type
Biologique
×
 
Titre de l'étude
Statut
An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults NCT07467707
Pas encore en recrutement
Essai de comparabilité du vaccin mva-bn fabriqué dans différentes cellules de production NCT07199569
En recrutement
A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children. NCT07003984
En recrutement
A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine NCT06899802
Actif, ne recrute pas
Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC (PregInPoxVac) NCT06844487
En recrutement
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination NCT06007183
Actif, ne recrute pas
Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years NCT05349617
TerminéRésultats publiés
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 NCT05329220
TerminéRésultats publiés
MVA-BN-RSV Vaccine Trial NCT05238025
InterrompuRésultats publiés
ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects NCT05077267
TerminéRésultats publiés
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine) NCT05072080
TerminéRésultats publiés
A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine (CHIKV VLP) NCT05065983
TerminéRésultats publiés
Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy Adults NCT04752644
Terminé
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer NCT04246671
Terminé
A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer NCT04134312
Terminé
Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects NCT04131595
Terminé
Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317) (WRAIR) NCT03992872
TerminéRésultats publiés
Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial NCT03699124
TerminéRésultats publiés
CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer NCT03628716
TerminéRésultats publiés
BN Brachyury and Radiation in Chordoma NCT03595228
TerminéRésultats publiés
A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC NCT03547999
InterrompuRésultats publiés
Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults NCT03483961
TerminéRésultats publiés
Special Access Program IMVAMUNE® NCT03472014
TerminéRésultats publiés
Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma NCT03376659
InterrompuRésultats publiés
Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury) NCT03349983
Terminé
VAXCHORA Pediatric Study to Assess Safety and Immunogenicity NCT03220737
TerminéRésultats publiés
JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo NCT02977715
Actif, ne recrute pas
RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults NCT02873286
TerminéRésultats publiés
RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults. NCT02864628
Retiré
A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer NCT02840994
Terminé
Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo NCT02661464
InterrompuRésultats publiés
Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine NCT02419391
Terminé
Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers NCT02391909
Terminé
A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults NCT02100631
TerminéRésultats publiés
A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults NCT02094586
TerminéRésultats publiés
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection NCT02038881
TerminéRésultats publiés
A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000® NCT01913353
TerminéRésultats publiés
Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera NCT01895855
TerminéRésultats publiés
A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects NCT01668537
TerminéRésultats publiés
Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200 NCT01585181
Terminé